Elizabeth C Mormino1, Reisa A Sperling2, Avram J Holmes2, Randy L Buckner2, Philip L De Jager2, Jordan W Smoller2, Mert R Sabuncu2. 1. From the Departments of Neurology (E.C.M., R.A.S.) and Radiology (R.A.S.), Massachusetts General Hospital, Harvard Medical School, Charlestown; Center for Alzheimer Research and Treatment, Department of Neurology (R.A.S.), and Program in Translational NeuroPsychiatric Genomics, Institute for the Neurosciences, Departments of Neurology and Psychiatry (P.L.D.), Brigham and Women's Hospital, Harvard Medical School (P.L.D.), Boston, MA; Department of Psychology (A.J.H.), Yale University, New Haven, CT; Department of Psychiatry (A.J.H.), Massachusetts General Hospital, Harvard Medical School, Boston; Athinoula A. Martinos Center for Biomedical Imaging (A.J.H.) and Psychiatric and Neurodevelopmental Genetics Unit, Center for Human Genetic Research (J.W.S.), Massachusetts General Hospital, Boston; Department of Psychology and Center for Brain Science (R.L.B.), Harvard University, Cambridge; Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology (R.L.B., M.R.S.), Massachusetts General Hospital, Charlestown; Program in Medical and Population Genetics (P.L.D.), Broad Institute; Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard (J.W.S.); and Computer Science and Artificial Intelligence Laboratory, Massachusetts Institute of Technology, Cambridge. bmormino@nmr.mgh.harvard.edu. 2. From the Departments of Neurology (E.C.M., R.A.S.) and Radiology (R.A.S.), Massachusetts General Hospital, Harvard Medical School, Charlestown; Center for Alzheimer Research and Treatment, Department of Neurology (R.A.S.), and Program in Translational NeuroPsychiatric Genomics, Institute for the Neurosciences, Departments of Neurology and Psychiatry (P.L.D.), Brigham and Women's Hospital, Harvard Medical School (P.L.D.), Boston, MA; Department of Psychology (A.J.H.), Yale University, New Haven, CT; Department of Psychiatry (A.J.H.), Massachusetts General Hospital, Harvard Medical School, Boston; Athinoula A. Martinos Center for Biomedical Imaging (A.J.H.) and Psychiatric and Neurodevelopmental Genetics Unit, Center for Human Genetic Research (J.W.S.), Massachusetts General Hospital, Boston; Department of Psychology and Center for Brain Science (R.L.B.), Harvard University, Cambridge; Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology (R.L.B., M.R.S.), Massachusetts General Hospital, Charlestown; Program in Medical and Population Genetics (P.L.D.), Broad Institute; Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard (J.W.S.); and Computer Science and Artificial Intelligence Laboratory, Massachusetts Institute of Technology, Cambridge.
Abstract
OBJECTIVE: To examine associations between aggregate genetic risk and Alzheimer disease (AD) markers in stages preceding the clinical symptoms of dementia using data from 2 large observational cohort studies. METHODS: We computed polygenic risk scores (PGRS) using summary statistics from the International Genomics of Alzheimer's Project genome-wide association study of AD. Associations between PGRS and AD markers (cognitive decline, clinical progression, hippocampus volume, and β-amyloid) were assessed within older participants with dementia. Associations between PGRS and hippocampus volume were additionally examined within healthy younger participants (age 18-35 years). RESULTS: Within participants without dementia, elevated PGRS was associated with worse memory (p = 0.002) and smaller hippocampus (p = 0.002) at baseline, as well as greater longitudinal cognitive decline (memory: p = 0.0005, executive function: p = 0.01) and clinical progression (p < 0.00001). High PGRS was associated with AD-like levels of β-amyloid burden as measured with florbetapir PET (p = 0.03) but did not reach statistical significance for CSF β-amyloid (p = 0.11). Within the younger group, higher PGRS was associated with smaller hippocampus volume (p = 0.05). This pattern was evident when examining a PGRS that included many loci below the genome-wide association study (GWAS)-level significance threshold (16,123 single nucleotide polymorphisms), but not when PGRS was restricted to GWAS-level significant loci (18 single nucleotide polymorphisms). CONCLUSIONS: Effects related to common genetic risk loci distributed throughout the genome are detectable among individuals without dementia. The influence of this genetic risk may begin in early life and make an individual more susceptible to cognitive impairment in late life. Future refinement of polygenic risk scores may help identify individuals at risk for AD dementia.
OBJECTIVE: To examine associations between aggregate genetic risk and Alzheimer disease (AD) markers in stages preceding the clinical symptoms of dementia using data from 2 large observational cohort studies. METHODS: We computed polygenic risk scores (PGRS) using summary statistics from the International Genomics of Alzheimer's Project genome-wide association study of AD. Associations between PGRS and AD markers (cognitive decline, clinical progression, hippocampus volume, and β-amyloid) were assessed within older participants with dementia. Associations between PGRS and hippocampus volume were additionally examined within healthy younger participants (age 18-35 years). RESULTS: Within participants without dementia, elevated PGRS was associated with worse memory (p = 0.002) and smaller hippocampus (p = 0.002) at baseline, as well as greater longitudinal cognitive decline (memory: p = 0.0005, executive function: p = 0.01) and clinical progression (p < 0.00001). High PGRS was associated with AD-like levels of β-amyloid burden as measured with florbetapir PET (p = 0.03) but did not reach statistical significance for CSF β-amyloid (p = 0.11). Within the younger group, higher PGRS was associated with smaller hippocampus volume (p = 0.05). This pattern was evident when examining a PGRS that included many loci below the genome-wide association study (GWAS)-level significance threshold (16,123 single nucleotide polymorphisms), but not when PGRS was restricted to GWAS-level significant loci (18 single nucleotide polymorphisms). CONCLUSIONS: Effects related to common genetic risk loci distributed throughout the genome are detectable among individuals without dementia. The influence of this genetic risk may begin in early life and make an individual more susceptible to cognitive impairment in late life. Future refinement of polygenic risk scores may help identify individuals at risk for AD dementia.
Authors: Laura E Gibbons; Adam C Carle; R Scott Mackin; Danielle Harvey; Shubhabrata Mukherjee; Philip Insel; S McKay Curtis; Dan Mungas; Paul K Crane Journal: Brain Imaging Behav Date: 2012-12 Impact factor: 3.978
Authors: Joshua M Shulman; Kewei Chen; Brendan T Keenan; Lori B Chibnik; Adam Fleisher; Pradeep Thiyyagura; Auttawut Roontiva; Cristin McCabe; Nikolaos A Patsopoulos; Jason J Corneveaux; Lei Yu; Matthew J Huentelman; Denis A Evans; Julie A Schneider; Eric M Reiman; Philip L De Jager; David A Bennett Journal: JAMA Neurol Date: 2013-09-01 Impact factor: 18.302
Authors: Tian Ge; Thomas E Nichols; Phil H Lee; Avram J Holmes; Joshua L Roffman; Randy L Buckner; Mert R Sabuncu; Jordan W Smoller Journal: Proc Natl Acad Sci U S A Date: 2015-02-09 Impact factor: 11.205
Authors: Eric M Reiman; Jessica B S Langbaum; Adam S Fleisher; Richard J Caselli; Kewei Chen; Napatkamon Ayutyanont; Yakeel T Quiroz; Kenneth S Kosik; Francisco Lopera; Pierre N Tariot Journal: J Alzheimers Dis Date: 2011 Impact factor: 4.472
Authors: Richard J Caselli; Amylou C Dueck; David Osborne; Marwan N Sabbagh; Donald J Connor; Geoffrey L Ahern; Leslie C Baxter; Steven Z Rapcsak; Jiong Shi; Bryan K Woodruff; Dona E C Locke; Charlene Hoffman Snyder; Gene E Alexander; Rosa Rademakers; Eric M Reiman Journal: N Engl J Med Date: 2009-07-16 Impact factor: 91.245
Authors: Victor L Villemagne; Samantha Burnham; Pierrick Bourgeat; Belinda Brown; Kathryn A Ellis; Olivier Salvado; Cassandra Szoeke; S Lance Macaulay; Ralph Martins; Paul Maruff; David Ames; Christopher C Rowe; Colin L Masters Journal: Lancet Neurol Date: 2013-03-08 Impact factor: 44.182
Authors: Avram J Holmes; Marisa O Hollinshead; Timothy M O'Keefe; Victor I Petrov; Gabriele R Fariello; Lawrence L Wald; Bruce Fischl; Bruce R Rosen; Ross W Mair; Joshua L Roffman; Jordan W Smoller; Randy L Buckner Journal: Sci Data Date: 2015-07-07 Impact factor: 6.444
Authors: Andrew B Wolf; Jon Valla; Guojun Bu; Jungsu Kim; Mary Jo LaDu; Eric M Reiman; Richard J Caselli Journal: Alzheimers Res Ther Date: 2013-09-03 Impact factor: 6.982
Authors: Gary W Beecham; Kara Hamilton; Adam C Naj; Eden R Martin; Matt Huentelman; Amanda J Myers; Jason J Corneveaux; John Hardy; Jean-Paul Vonsattel; Steven G Younkin; David A Bennett; Philip L De Jager; Eric B Larson; Paul K Crane; M Ilyas Kamboh; Julia K Kofler; Deborah C Mash; Linda Duque; John R Gilbert; Harry Gwirtsman; Joseph D Buxbaum; Patricia Kramer; Dennis W Dickson; Lindsay A Farrer; Matthew P Frosch; Bernardino Ghetti; Jonathan L Haines; Bradley T Hyman; Walter A Kukull; Richard P Mayeux; Margaret A Pericak-Vance; Julie A Schneider; John Q Trojanowski; Eric M Reiman; Gerard D Schellenberg; Thomas J Montine Journal: PLoS Genet Date: 2014-09-04 Impact factor: 5.917
Authors: Goncalo R Abecasis; Adam Auton; Lisa D Brooks; Mark A DePristo; Richard M Durbin; Robert E Handsaker; Hyun Min Kang; Gabor T Marth; Gil A McVean Journal: Nature Date: 2012-11-01 Impact factor: 49.962
Authors: Luiza K Axelrud; Marcos L Santoro; Daniel S Pine; Fernanda Talarico; Ary Gadelha; Gisele G Manfro; Pedro M Pan; Andrea Jackowski; Felipe Picon; Elisa Brietzke; Rodrigo Grassi-Oliveira; Rodrigo A Bressan; Eurípedes C Miguel; Luis A Rohde; Hakon Hakonarson; Zdenka Pausova; Sintia Belangero; Tomas Paus; Giovanni A Salum Journal: Am J Psychiatry Date: 2018-03-02 Impact factor: 18.112
Authors: Rachel L Nosheny; Philip S Insel; Niklas Mattsson; Duygu Tosun; Shannon Buckley; Diana Truran; N Schuff; Paul S Aisen; Michael W Weiner Journal: Neurobiol Aging Date: 2019-07-22 Impact factor: 4.673
Authors: Luiza Kvitko Axelrud; João Ricardo Sato; Marcos Leite Santoro; Fernanda Talarico; Daniel Samuel Pine; Luis Augusto Rohde; Andre Zugman; Edson Amaro Junior; Rodrigo Affonseca Bressan; Rodrigo Grassi-Oliveira; Pedro Mario Pan; Maurício Scopel Hoffmann; Andre Rafael Simioni; Salvador Martin Guinjoan; Hakon Hakonarson; Elisa Brietzke; Ary Gadelha; Renata Pellegrino da Silva; Marcelo Queiroz Hoexter; Euripedes Constantino Miguel; Sintia Iole Belangero; Giovanni Abrahão Salum Journal: Neurobiol Aging Date: 2019-07-06 Impact factor: 4.673
Authors: Burcu F Darst; Rebecca L Koscik; Annie M Racine; Jennifer M Oh; Rachel A Krause; Cynthia M Carlsson; Henrik Zetterberg; Kaj Blennow; Bradley T Christian; Barbara B Bendlin; Ozioma C Okonkwo; Kirk J Hogan; Bruce P Hermann; Mark A Sager; Sanjay Asthana; Sterling C Johnson; Corinne D Engelman Journal: J Alzheimers Dis Date: 2017 Impact factor: 4.472
Authors: Chin Hong Tan; Luke W Bonham; Chun Chieh Fan; Elizabeth C Mormino; Leo P Sugrue; Iris J Broce; Christopher P Hess; Jennifer S Yokoyama; Gil D Rabinovici; Bruce L Miller; Kristine Yaffe; Gerard D Schellenberg; Karolina Kauppi; Dominic Holland; Linda K McEvoy; Walter A Kukull; Duygu Tosun; Michael W Weiner; Reisa A Sperling; David A Bennett; Bradley T Hyman; Ole A Andreassen; Anders M Dale; Rahul S Desikan Journal: Brain Date: 2019-02-01 Impact factor: 13.501